Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of type 2 diabetes mellitus~* patients with hypertension (seated office SBP of \>=130 mmHg and \<160 mmHg and seated office DBP of \>= 70 mmHg at screening and at Week -2~* patients on stable doses of 1 to 3 anti-hypertensive agents for at least 5 weeks before screening~* patients on stable doses of 1 to 3 oral anti-hyperglycemic agents which must include metformin, for at least 8 weeks before screening~Exclusion Criteria:~* a history of diabetic ketoacidosis~* type 1 diabetes mellitus (T1DM)~* pancreas or beta-cell transplantation~* fasting C-peptide \<0.70 ng/mL (0.23 nmol/L)~* body mass index \<30 kg/m2~* has ongoing, inadequately controlled thyroid disorder~* has a history of cardio-renal disease that required treatment with immunosuppressive therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).